It all starts
with the
discovery
of new
modes of action
Target discovery platform
Filgotinib, a selective JAK1-inhibitor which has shown activity and favorable tolerability in inflammatory diseases.
A tiny molecule – yet,
what it can do is
unimaginably
big
Filgotinib
GLPG1690, a potent and selective inhibitor of autotaxin, a potential target for IPF.
Innovative medicines
can
change
people’s
lives
The Galapagos pipeline
As many
medical
innovations
have done before
Strategy
Clockwise: single microscope, Antoni van Leeuwenhoek (1673-1723); heart valve prosthesis (1970-1990); artificial kidney, Willem Johan Kolff (1943); bottle with penicillin, Royal Dutch Yeast and Spiritus factory (1950-1975); hearing aid (1875-1950).
To date,
we have
three novel
mechanisms
showing promising
patient results
R&D
Clockwise: small molecule filgotinib, small molecule GLPG1690 and monoclonal antibody MOR106.
Letter from the management
Corporate social responsibility
We believe we have a responsibility to ensure our actions not only benefit our main stakeholders, but also society as a whole. At Galapagos, being socially responsible is already a consideration in everything we do.
Read more